Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | ACE2016 |
Synonyms | |
Therapy Description |
ACE2016 are EGFR-targeting T-cells that potentially inhibit growth of EGFR-expressing cancer cells (Cancer Res (2023) 83 (8_Supplement): LB089). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ACE2016 | ACE 2016|ACE-2016 | EGFR Immune Cell Therapy 4 | ACE2016 are EGFR-targeting T-cells that potentially inhibit growth of EGFR-expressing cancer cells (Cancer Res (2023) 83 (8_Supplement): LB089). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06415487 | Phase I | Cyclophosphamide + Fludarabine ACE2016 + Pembrolizumab ACE2016 | ACE2016 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR) | Not yet recruiting | USA | 0 |